The Venture Codex Logo

The Venture Codex

Wyss Zurich

Weinbergstrasse 35, Zürich, Zurich, 8092, Switzerland

Overview

Wyss Zurich is a joint accelerator of the University of Zurich and ETH Zurich (Swiss Federal Institute of Technology Zurich), which was made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. h.c. mult. Hansjörg Wyss. It was established to foster translational research focused on developing treatment protocols and clinical therapies, as well as novel technologies and intelligent systems, in the emerging fields of Regenerative Medicine and Robotics, and hybrid technologies thereof. Wyss Zurich unites world-leading experts from both institutions in multidisciplinary teams, pooling their knowledge and expertise.

Total investments
1
Lead investments
0
Investments · 12mo
0
Active investors
0

Sector focus

  • Business Development
  • Consulting
  • Finance
  • Financial Services
Visit website

Investment portfolio

  • MUVON Therapeutics

    Participated · Series A · May 2021

    Muvon Therapeutics is developing an autologous cell therapy using patients' own muscle precursor cells (MPCs) to regenerate damaged sphincter and other skeletal muscle tissue, with electromagnetic stimulation supporting regeneration. The company's lead program targets stress urinary incontinence (SUI), initially focused on women, and is positioned as a minimally invasive, low‑risk therapy that uses no foreign materials. Preclinical work at the University of Zurich over 12 years showed nearly 90% recovery of original muscle strength six months after injection. Muvon began first‑in‑human studies (first patient treated March 2020) and the phase 1 study is proceeding toward finalization, with final results expected this autumn. The startup is a University of Zurich spin‑off, currently employs seven people, and has joined the Wyss Zurich incubator to support clinical development. Planned next steps include completing clinical studies and scaling up production by automating the manufacturing cycle to address a large patient population with SUI.

Team

No current team members are available.